Status:

ACTIVE_NOT_RECRUITING

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborating Sponsors:

Advanced Accelerator Applications

Conditions:

Neuroendocrine Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radi...

Eligibility Criteria

Inclusion

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female ≥ 18 years old
  • Histologically confirmed diagnosis of poorly-differentiated neuroendocrine carcinoma of the gastroenteropancreatic tract or unknown primary
  • Evidence of measurable disease per RECIST 1.1 on another imagine modality (CT, MRI or FDGPET) with at least 3 tumors \>1cm in largest diameter. CT, MRI or Fluorodeoxyglucose (FDG)-PET must have been performed within 2 months of the study scan. (Of note, participants may sign consent for the study prior to scheduling of said CT, MRI or FDG-PET, but will be considered screen failures if the CT/MRI/FDG-PET does not reveal at least 3 tumors \>1cm).

Exclusion

  • Participants with well-differentiated neuroendocrine tumors
  • Participants who have undergone 68Ga-dotatate PET scan in the past
  • Pregnant women and/or breastfeeding women. Women of child bearing potential must have a negative pregnancy test prior to scan.

Key Trial Info

Start Date :

September 25 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2026

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04069299

Start Date

September 25 2019

End Date

January 1 2026

Last Update

December 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

H Lee Moffitt Cancer & Research Institute

Tampa, Florida, United States, 33612